U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Myelofibrosis

MedGen UID:
1694775
•Concept ID:
C5206559
•
Disease or Syndrome

Definition

Myelofibrosis that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Myelofibrosis

Professional guidelines

PubMed

Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
Scherber RM, Mesa RA
Blood Rev 2020 Jul;42:100716. Epub 2020 May 30 doi: 10.1016/j.blre.2020.100716. PMID: 32593470Free PMC Article

Recent clinical studies

Etiology

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, Xia Q, Zhu E, Feller F, Rizo A, Bussolari J, Wan Y, Komrokji R
Ann Hematol 2022 Jan;101(1):139-146. Epub 2021 Oct 8 doi: 10.1007/s00277-021-04683-w. PMID: 34622316
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ
J Clin Oncol 2021 Sep 10;39(26):2881-2892. Epub 2021 Jun 17 doi: 10.1200/JCO.20.02864. PMID: 34138638
Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
Scherber RM, Mesa RA
Blood Rev 2020 Jul;42:100716. Epub 2020 May 30 doi: 10.1016/j.blre.2020.100716. PMID: 32593470Free PMC Article
Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A, Su D, Martynova A, Pannell B, Mukherjee S, O'Neill C, Sekeres M, O'Connell C
Clin Lymphoma Myeloma Leuk 2018 Nov;18(11):e463-e468. Epub 2018 Jun 28 doi: 10.1016/j.clml.2018.06.025. PMID: 30115545

Diagnosis

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, Xia Q, Zhu E, Feller F, Rizo A, Bussolari J, Wan Y, Komrokji R
Ann Hematol 2022 Jan;101(1):139-146. Epub 2021 Oct 8 doi: 10.1007/s00277-021-04683-w. PMID: 34622316

Therapy

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, Xia Q, Zhu E, Feller F, Rizo A, Bussolari J, Wan Y, Komrokji R
Ann Hematol 2022 Jan;101(1):139-146. Epub 2021 Oct 8 doi: 10.1007/s00277-021-04683-w. PMID: 34622316
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ
J Clin Oncol 2021 Sep 10;39(26):2881-2892. Epub 2021 Jun 17 doi: 10.1200/JCO.20.02864. PMID: 34138638
Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
Scherber RM, Mesa RA
Blood Rev 2020 Jul;42:100716. Epub 2020 May 30 doi: 10.1016/j.blre.2020.100716. PMID: 32593470Free PMC Article
Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A, Su D, Martynova A, Pannell B, Mukherjee S, O'Neill C, Sekeres M, O'Connell C
Clin Lymphoma Myeloma Leuk 2018 Nov;18(11):e463-e468. Epub 2018 Jun 28 doi: 10.1016/j.clml.2018.06.025. PMID: 30115545

Prognosis

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, Xia Q, Zhu E, Feller F, Rizo A, Bussolari J, Wan Y, Komrokji R
Ann Hematol 2022 Jan;101(1):139-146. Epub 2021 Oct 8 doi: 10.1007/s00277-021-04683-w. PMID: 34622316
Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
Scherber RM, Mesa RA
Blood Rev 2020 Jul;42:100716. Epub 2020 May 30 doi: 10.1016/j.blre.2020.100716. PMID: 32593470Free PMC Article
Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A, Su D, Martynova A, Pannell B, Mukherjee S, O'Neill C, Sekeres M, O'Connell C
Clin Lymphoma Myeloma Leuk 2018 Nov;18(11):e463-e468. Epub 2018 Jun 28 doi: 10.1016/j.clml.2018.06.025. PMID: 30115545

Clinical prediction guides

Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.
Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, Xia Q, Zhu E, Feller F, Rizo A, Bussolari J, Wan Y, Komrokji R
Ann Hematol 2022 Jan;101(1):139-146. Epub 2021 Oct 8 doi: 10.1007/s00277-021-04683-w. PMID: 34622316
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ
J Clin Oncol 2021 Sep 10;39(26):2881-2892. Epub 2021 Jun 17 doi: 10.1200/JCO.20.02864. PMID: 34138638

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...